This CPB has been revised to: (i) clarify the coverage criteria for transperineal stereotactic template-guided saturation prostate biopsy; (ii) state that transrectal ultrasound (TRUS)-guided prostate biopsy is considered medically necessary for diagnosis, follow-up, and active surveillance of prostate cancer when criteria are met; and (iii) transperineal or transrectal magnetic resonance imaging (MRI)-guided prostate biopsy (including the in-bore (direct) approach, and fusion imaging of multi-parametric MRI with TRUS (MRI-TRUS; e.g., the UroNav fusion biopsy system) medically necessary for diagnosis, follow-up, and active surveillance of prostate cancer when criteria are met.

The title of this CPB has been changed to "Prostate Biopsy".